Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapies

1 May 2024

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Virus-based gene therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38821669
DOI: 10.1016/j.mrgentox.2024.503767

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapiesPMID 38821669Read ↗

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory GuidelinesSemantic proximity Read ↗

Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methodsSemantic proximity Read ↗

Considerations for Cell and Gene Therapy Programs Entering the Clinical SpaceSemantic proximity Read ↗

Challenges and Pathways in Regulating Next-Gen Biological TherapiesSemantic proximity Read ↗

An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapiesSemantic proximity Read ↗

Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working GroupSemantic proximity Read ↗

Les débuts de CRISPR en thérapie géniqueSemantic proximity Read ↗

Cell-free DNA as a post-treatment surveillance strategy: current statusSemantic proximity Read ↗

Gene Therapy Leaves a Vicious CycleSemantic proximity Read ↗

Oncolytic viral therapies – the clinical experienceSemantic proximity Read ↗

A New Class of Medicines through DNA EditingSemantic proximity Read ↗

Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progressSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.